Literature DB >> 27402919

Nicotinamide Adenine Dinucleotide Phosphate Oxidase-Mediated Redox Signaling and Vascular Remodeling by 16α-Hydroxyestrone in Human Pulmonary Artery Cells: Implications in Pulmonary Arterial Hypertension.

Katie Y Hood1, Augusto C Montezano1, Adam P Harvey1, Margaret Nilsen1, Margaret R MacLean1, Rhian M Touyz2.   

Abstract

Estrogen and oxidative stress have been implicated in pulmonary arterial hypertension (PAH). Mechanisms linking these systems are elusive. We hypothesized that estrogen metabolite, 16α-hydroxyestrone (16αOHE1), stimulates nicotinamide adenine dinucleotide phosphate oxidase (Nox)-induced reactive oxygen species (ROS) generation and proliferative responses in human pulmonary artery smooth muscle cells (hPASMCs) and that in PAH aberrant growth signaling promotes vascular remodeling. The pathophysiological significance of estrogen-Nox-dependent processes was studied in female Nox1(-/-) and Nox4(-/-) mice with PAH. PASMCs from control subjects (control hPASMCs) and PAH patients (PAH-hPASMCs) were exposed to estrogen and 16αOHE1 in the presence/absence of inhibitors of Nox, cytochrome P450 1B1, and estrogen receptors. Estrogen, through estrogen receptor-α, increased Nox-derived ROS and redox-sensitive growth in hPASMCs, with greater effects in PAH-hPASMCs versus control hPASMCs. Estrogen effects were inhibited by cytochrome P450 1B1 blockade. 16αOHE1 stimulated transient ROS production in hPASMCs, with sustained responses in PAH-hPASMCs. Basal expression of Nox1/Nox4 was potentiated in PAH-hPASMCs. In hPASMCs, 16αOHE1 increased Nox1 expression, stimulated irreversible oxidation of protein tyrosine phosphatases, decreased nuclear factor erythroid-related factor 2 activity and expression of nuclear factor erythroid-related factor 2-regulated antioxidant genes, and promoted proliferation. This was further amplified in PAH-hPASMCs. Nox1(-/-) but not Nox4(-/-) mice were protected against PAH and vascular remodeling. Our findings demonstrate that in PAH-hPASMCs, 16αOHE1 stimulates redox-sensitive cell growth primarily through Nox1. Supporting this, in vivo studies exhibited protection against pulmonary hypertension and remodeling in Nox1(-/-) mice. This study provides new insights through Nox1/ROS and nuclear factor erythroid-related factor 2 whereby 16αOHE1 influences hPASMC function, which when upregulated may contribute to vascular injury in PAH, particularly important in women.
© 2016 The Authors.

Entities:  

Keywords:  NADPH oxidase; estrogens; hypertension, pulmonary; models, animal; superoxide

Mesh:

Substances:

Year:  2016        PMID: 27402919      PMCID: PMC4978604          DOI: 10.1161/HYPERTENSIONAHA.116.07668

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  44 in total

1.  Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner.

Authors:  Allan Lawrie; Abdul G Hameed; Janet Chamberlain; Nadine Arnold; Aneurin Kennerley; Kay Hopkinson; Josephine Pickworth; David G Kiely; David C Crossman; Sheila E Francis
Journal:  Am J Pathol       Date:  2011-08-09       Impact factor: 4.307

Review 2.  Estrogen receptors: therapies targeted to receptor subtypes.

Authors:  S Nilsson; J-Å Gustafsson
Journal:  Clin Pharmacol Ther       Date:  2010-12-01       Impact factor: 6.875

3.  Induction by estrogen metabolite 16 alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells.

Authors:  N T Telang; A Suto; G Y Wong; M P Osborne; H L Bradlow
Journal:  J Natl Cancer Inst       Date:  1992-04-15       Impact factor: 13.506

4.  Nox-derived ROS are acutely activated in pressure overload pulmonary hypertension: indications for a seminal role for mitochondrial Nox4.

Authors:  Giovanna Frazziano; Imad Al Ghouleh; Jeff Baust; Sruti Shiva; Hunter C Champion; Patrick J Pagano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-11-08       Impact factor: 4.733

5.  Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females.

Authors:  E D Austin; J D Cogan; J D West; L K Hedges; R Hamid; E P Dawson; L A Wheeler; F F Parl; J E Loyd; J A Phillips
Journal:  Eur Respir J       Date:  2009-04-08       Impact factor: 16.671

6.  Inhibition of NOX/VPO1 pathway and inflammatory reaction by trimethoxystilbene in prevention of cardiovascular remodeling in hypoxia-induced pulmonary hypertensive rats.

Authors:  Bin Liu; Xiu-Ju Luo; Zhong-Bao Yang; Jie-Jie Zhang; Ting-Bo Li; Xiao-Jie Zhang; Qi-Lin Ma; Guo-Gang Zhang; Chang-Ping Hu; Jun Peng
Journal:  J Cardiovasc Pharmacol       Date:  2014-06       Impact factor: 3.105

Review 7.  Myc and cell cycle control.

Authors:  Gabriel Bretones; M Dolores Delgado; Javier León
Journal:  Biochim Biophys Acta       Date:  2014-04-01

8.  Parameters of ventricular contractility in mice: influence of load and sensitivity to changes in inotropic state.

Authors:  An Van den Bergh; Willem Flameng; Paul Herijgers
Journal:  Pflugers Arch       Date:  2007-10-12       Impact factor: 3.657

9.  Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension.

Authors:  Kevin White; Anne Katrine Johansen; Margaret Nilsen; Loredana Ciuclan; Emma Wallace; Leigh Paton; Annabel Campbell; Ian Morecroft; Lynn Loughlin; John D McClure; Matthew Thomas; Kirsty M Mair; Margaret R MacLean
Journal:  Circulation       Date:  2012-08-02       Impact factor: 29.690

Review 10.  Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response.

Authors:  K M Mair; A K Z Johansen; A F Wright; E Wallace; M R MacLean
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

View more
  33 in total

1.  Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.

Authors:  Xinping Chen; Eric D Austin; Megha Talati; Joshua P Fessel; Eric H Farber-Eger; Evan L Brittain; Anna R Hemnes; James E Loyd; James West
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 2.  Cellular Pathways Promoting Pulmonary Vascular Remodeling by Hypoxia.

Authors:  Larissa A Shimoda
Journal:  Physiology (Bethesda)       Date:  2020-07-01

3.  Insights from the Menstrual Cycle in Pulmonary Arterial Hypertension.

Authors:  Grayson L Baird; Thomas Walsh; Jason Aliotta; Melissa Allahua; Ruth Andrew; Ghada Bourjeily; Alexander S Brodsky; Nina Denver; Mark Dooner; Elizabeth O Harrington; James R Klinger; Margaret R MacLean; Christopher J Mullin; Mandy Pereira; Athena Poppas; Mary Whittenhall; Corey E Ventetuolo
Journal:  Ann Am Thorac Soc       Date:  2021-02

4.  Role of curcumin in PLD activation by Arf6-cytohesin1 signaling axis in U46619-stimulated pulmonary artery smooth muscle cells.

Authors:  Sajal Chakraborti; Jaganmay Sarkar; Rajabrata Bhuyan; Tapati Chakraborti
Journal:  Mol Cell Biochem       Date:  2017-08-05       Impact factor: 3.396

5.  Sex differences in the proliferation of pulmonary artery endothelial cells: implications for plexiform arteriopathy.

Authors:  Shanshan Qin; Dan N Predescu; Monal Patel; Patrick Drazkowski; Balaji Ganesh; Sanda A Predescu
Journal:  J Cell Sci       Date:  2020-05-14       Impact factor: 5.285

6.  Novel Regulators and Targets of Redox Signaling in Pulmonary Vasculature.

Authors:  Zdravka Daneva; Victor E Laubach; Swapnil K Sonkusare
Journal:  Curr Opin Physiol       Date:  2019-05-09

7.  Role of the Aryl Hydrocarbon Receptor in Sugen 5416-induced Experimental Pulmonary Hypertension.

Authors:  Afshan Dean; Teja Gregorc; Craig K Docherty; Katie Y Harvey; Margaret Nilsen; Nicholas W Morrell; Margaret R MacLean
Journal:  Am J Respir Cell Mol Biol       Date:  2018-03       Impact factor: 6.914

Review 8.  Redox Stress Defines the Small Artery Vasculopathy of Hypertension: How Do We Bridge the Bench-to-Bedside Gap?

Authors:  Rhian M Touyz; Augusto C Montezano; Francisco Rios; Michael E Widlansky; Mingyu Liang
Journal:  Circ Res       Date:  2017-05-26       Impact factor: 17.367

9.  Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2).

Authors:  Michael B Fallon; Steven M Kawut; Nadine Al-Naamani; Michael J Krowka; Kimberly A Forde; Karen L Krok; Rui Feng; Gustavo A Heresi; Raed A Dweik; Sonja Bartolome; Todd M Bull; Kari E Roberts; Eric D Austin; Anna R Hemnes; Mamta J Patel; Jae K Oh; Grace Lin; Margaret F Doyle; Nina Denver; Ruth Andrew; Margaret R MacLean
Journal:  Hepatology       Date:  2020-09-29       Impact factor: 17.425

10.  Up-Regulation of the Long Noncoding RNA X-Inactive-Specific Transcript and the Sex Bias in Pulmonary Arterial Hypertension.

Authors:  Shanshan Qin; Dan Predescu; Brandon Carman; Priyam Patel; Jiwang Chen; Miran Kim; Tim Lahm; Mark Geraci; Sanda A Predescu
Journal:  Am J Pathol       Date:  2021-04-06       Impact factor: 5.770

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.